Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q3 2022 -- -0.41 --
08/03/2022 -- Results Q2 2022 -0.31 -0.36 14.48%
05/10/2022 -- Results Q1 2022 -0.31 -0.41 24.85%
02/24/2022 -- Results Q4 2021 -0.37 -0.36 -2.07%
11/02/2021 -- Results Q3 2021 -0.35 -0.28 -25.00%
08/05/2021 -- Results Q2 2021 -0.34 -0.28 -21.43%
05/07/2021 -- Results Q1 2021 -0.57 -0.28 -103.6%
02/25/2021 -- Results Q4 2020 -0.31 -0.26 -19.96%
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since 16.39%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
URL https://www.aclaristx.com
Investor Relations URL https://www.aclaristx.com/#!investors/juser
HQ State/Province Pennsylvania
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
0.74%
-9.14%
-70.03%
-74.42%
242.3%
124.7%
15.27%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.98%
--
--
--
--
94.97%
-27.56%
-20.42%
-57.31%
-26.80%
3.27%
-40.49%
-3.15%
-17.50%
168.2%
-43.62%
-44.09%
24.03%
-56.22%
-55.56%
-5.00%
71.93%
-34.35%
-78.76%
-53.05%
--
-85.15%
37.29%
-56.05%
-78.69%
84.55%
-22.23%
-31.80%
As of August 15, 2022.

Profile

Edit
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
URL https://www.aclaristx.com
Investor Relations URL https://www.aclaristx.com/#!investors/juser
HQ State/Province Pennsylvania
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
LYFCX 1.121M USD 3.54%
FNDRX 158177.0 USD 0.32%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ACRS Tweets